147 related articles for article (PubMed ID: 9179263)
1. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein.
Han S; Yun IJ; Noh DY; Choe KJ; Song SY; Chi JG
J Surg Oncol; 1997 May; 65(1):22-7. PubMed ID: 9179263
[TBL] [Abstract][Full Text] [Related]
2. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation.
Bertheau P; Steinberg SM; Merino MJ
Hum Pathol; 1998 Apr; 29(4):323-9. PubMed ID: 9563780
[TBL] [Abstract][Full Text] [Related]
3. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
[TBL] [Abstract][Full Text] [Related]
4. Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.
Nakopoulou LL; Tsitsimelis D; Lazaris AC; Tzonou A; Gakiopoulou H; Dicoglou CC; Davaris PS
Cancer Detect Prev; 1999; 23(4):297-308. PubMed ID: 10403901
[TBL] [Abstract][Full Text] [Related]
5. Potential markers predicting distant metastasis in axillary node-negative breast carcinoma.
Niu Y; Fu X; Lv A; Fan Y; Wang Y
Int J Cancer; 2002 Apr; 98(5):754-60. PubMed ID: 11920647
[TBL] [Abstract][Full Text] [Related]
6. nm23--relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients.
Russell RL; Geisinger KR; Mehta RR; White WL; Shelton B; Kute TE
Cancer; 1997 Mar; 79(6):1158-65. PubMed ID: 9070493
[TBL] [Abstract][Full Text] [Related]
7. Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation.
Belev B; Alerić I; Vrbanec D; Petrovecki M; Unusic J; Jakić-Razumović J
Acta Oncol; 2002; 41(4):355-61. PubMed ID: 12234027
[TBL] [Abstract][Full Text] [Related]
8. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
[TBL] [Abstract][Full Text] [Related]
9. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer.
Lee KE; Lee HJ; Kim YH; Yu HJ; Yang HK; Kim WH; Lee KU; Choe KJ; Kim JP
Jpn J Clin Oncol; 2003 Apr; 33(4):173-9. PubMed ID: 12810831
[TBL] [Abstract][Full Text] [Related]
12. Automated and quantitative immunocytochemical assays of Nm23/NDPK protein in breast carcinomas.
Charpin C; Bouvier C; Garcia S; Martini F; Andrac L; Lavaut MN; Allasia C
Int J Cancer; 1997 Aug; 74(4):416-20. PubMed ID: 9291431
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer.
Tokunaga Y; Urano T; Furukawa K; Kondo H; Kanematsu T; Shiku H
Int J Cancer; 1993 Aug; 55(1):66-71. PubMed ID: 8102131
[TBL] [Abstract][Full Text] [Related]
14. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer.
Iwaya K; Tsuda H; Fukutomi T; Tsugane S; Suzuki M; Hirohashi S
Jpn J Clin Oncol; 1997 Feb; 27(1):6-12. PubMed ID: 9070333
[TBL] [Abstract][Full Text] [Related]
15. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
16. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer.
Baekelandt M; Holm R; Tropé CG; Nesland JM; Kristensen GB
Ann Oncol; 1999 Nov; 10(11):1335-41. PubMed ID: 10631462
[TBL] [Abstract][Full Text] [Related]
17. Numerical aberrations of chromosome 17 in interphase cell nuclei of breast carcinoma cells: lack of correlation with abnormal expression of p53, neu and nm23 protein.
Sauer T; Beraki K; Jebsen PW; Ormerod E; Naess O
APMIS; 1998 Oct; 106(10):921-7. PubMed ID: 9833692
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer.
Midulla C; De Iorio P; Nagar C; Pisani T; Cenci M; Valli C; Nofroni I; Vecchione A
Anticancer Res; 1999; 19(5B):4033-7. PubMed ID: 10628350
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
